Michael Mollerus
Lawyers
Filters
Biotie Therapies Corp. Initial Public Offering
Davis Polk advised Biotie Therapies Corp. (“Biotie”) on its $56.7 million U.S. initial public offering of 3,806,047 American Depositary Shares (“ADSs”) representing 304,483,760 ordinary…
Davis Polk Advises Verisk Analytics on Its $1.25 Billion Senior Notes Offering
Davis Polk advised Verisk Analytics, Inc. on its SEC-registered offering of $900 million aggregate principal amount of 4.000% senior notes due 2025 and $350 million aggregate principal…
Davis Polk Advises Verisk Analytics on Its $742 Million Follow-On Offering
Davis Polk advised Verisk Analytics, Inc. on its SEC-registered follow-on public offering of 10,604,000 shares of Class A common stock including 964,000 shares that the underwriters…
Davis Polk Advises Kosmos Energy Ltd. On Its $225 Million High-Yield Notes Offering
Davis Polk advised Kosmos Energy Ltd. in connection with a Rule 144A/Regulation S offering of an additional $225 million aggregate principal amount of its 7.875% senior secured notes due…
Warner Chilcott $8.5 billion acquisition by Actavis
Davis Polk is advising Warner Chilcott plc in connection with its approximately $8.5 billion acquisition by Actavis, Inc. in a stock-for-stock transaction. The transaction is expected to…